EyePoint Stock Craters 71% After Drug Trial Failure. It May Be an Overreaction.

Duravyu, EyePoint's candidate for wet age-related macular degeneration, misses the mark, but muddled trial data may be to blame.

Source: Barrons

Visit Source

0 0 0

Comment

Important Notice: More than 48 hours have passed since this news or analysis was published. Due to the volatility of financial markets, some of the information or data presented may no longer be valid or reflect current market conditions. Please verify the information again before making any trading or investment decisions.

Comments

No comments yet

Be the first person to comment on this news item.

Category General

Source Barrons

Published 1 month ago

Likes 0

Comments 0

Shares 0

News ID #7,294

Status Published

This news may have been collected automatically from third-party sources. Please verify important information through the original source and other reliable sources before making any trading or investment decision. This content is provided for informational purposes only and does not constitute financial advice.

Keep comments relevant to the news topic and avoid offensive, promotional, spam, or misleading content.